SCL Science Inc, formerly InnoTherapy Inc, is a Korea-based company principally engaged in the research, development, manufacture, export and sale of medical hemostatic agents. The main developed products include medical hemostats and sealants with biomimetic technology. In addition, the Company is engaged in the bio-logistics business.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	₩2,620.00	-6.26%	250,495
29/09/26	₩2,795.00	-2.78%	388,861
28/09/26	₩2,875.00	+5.70%	319,585
23/09/26	₩2,720.00	+11.25%	477,149
22/09/26	₩2,445.00	+0.82%	127,444

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 29/09/2026			5-day change	1st Jan Change
2,795.00 ^KRW	-2.78%		+14.31%	+21.52%

08-14	SCL Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	89.12B 65.71M 57.99M 54.86M 49.76M 93.28M 6.31B 94.2M 658M 254M 3.22B 247M 241M 10.36B	P/E 2024	-16x	P/E 2025	-19.2x
Enterprise Value	112B 82.32M 72.65M 68.74M 62.34M 117M 7.9B 118M 825M 318M 4.03B 309M 302M 12.98B	EV / Sales 2024	13.3x	EV / Sales 2025	4.57x
Free-Float	45.72%	Yield 2024 *	-	Yield 2025	-

08-14	SCL Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	SCL Science Inc. agreed to acquire Bio-logistics business in Honam region of Seoul Clinical Laboratories for KRW 4.3 billion.	CI
11-14	SCL Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11/09/25	Scl Science to acquire 1.6 billion won worth of shares and majority stake in Pentamedix Co Ltd	RE
10/09/25	SCL Science Inc. agreed to acquire 60.31% stake in PentaMedix Co., Ltd. for KRW 1.6 billion.	CI
14/08/25	Scl Science wins 530 million won order	RE
14/08/25	SCL Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
28/07/25	SCL Science Inc. agreed to acquire Bio-logistics business in Yeongnam region of Seoul Clinical Laboratories from Seoul Clinical Laboratories for KRW 5.0 billion.	CI
15/05/25	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
30/03/25	SCL Science Inc. completed the acquisition of SCL Healthcare Co., Ltd.	CI
20/03/25	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

1 day	-2.78%
1 week	+14.31%
Current month	+21.52%
1 month	+26.76%
3 months	+69.39%
6 months	+25.06%
Current year	+21.52%

SCL Science Inc. Share Price

Stocks

A246960

KR7246960009

Pharmaceuticals

Valuation: SCL Science Inc.

Chart: SCL Science Inc.

Latest news: SCL Science Inc.

Quotes and Performance

Price Extremes

Managers and Directors: SCL Science Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

1 week	2,580	2,920
1 month	2,130	2,920
Current year	1,389	2,920
1 year	1,389	3,250
3 years	1,389	5,110
5 years	1,389	5,110
10 years	1,300	6,950

Manager	Title	Age	Since
Kyung-Yul Lee CEO	Chief Executive Officer	-	27/12/2022
Se-Yeon Baek CEO	Chief Executive Officer	59	29/09/2024
Dae-Young Kim AUD	Comptroller/Controller/Auditor	63	27/12/2022

Director	Title	Age	Since
Se-Yeon Baek BRD	Director/Board Member	59	29/09/2024
Jeong-Gyun Choi BRD	Director/Board Member	59	29/09/2024
Kyung-Yul Lee BRD	Director/Board Member	-	27/12/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
11/08/25	Chang-ho Jin	Free		12,798	0.0377%
11/08/25	Se-Yeon Baek	Free	Chief Executive Officer	28,500	0.0840%
11/08/25	Han-Jo Kim	Free		1,359	0.0040%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCL SCIENCE INC.	-2.78%	+14.31%	+9.18%	+31.22%	70.1M
ELI LILLY AND COMPANY	+0.22%	+3.52%	+56.16%	+121.34%	1,056B
JOHNSON & JOHNSON	+0.04%	-0.92%	+43.84%	+71.90%	645B
ABBVIE INC.	-0.01%	-0.56%	+13.85%	+77.81%	465B
MERCK & CO., INC.	-1.18%	-0.50%	+75.55%	+43.68%	368B
ROCHE HOLDING AG	-0.06%	-3.96%	+34.21%	+40.62%	335B
NOVARTIS AG	-0.18%	+2.47%	+20.36%	+29.06%	275B
ASTRAZENECA PLC	-0.86%	-1.06%	+9.98%	+12.31%	255B
AMGEN INC.	-0.33%	+4.01%	+49.67%	+58.60%	229B
GILEAD SCIENCES, INC.	-0.72%	-0.90%	+35.14%	+102.44%	188B
Average	-0.56%	+1.64%	+34.79%	+58.90%	381.58B
Weighted average by Cap.	-0.17%	+0.30%	+41.77%	+74.47%

	2024	2025
Net sales	4.74B 3.49M 3.08M 2.92M 2.64M 4.96M 335M 5.01M 34.99M 13.48M 171M 13.12M 12.83M 551M	22.01B 16.23M 14.32M 13.55M 12.29M 23.04M 1.56B 23.27M 163M 62.65M 795M 60.94M 59.61M 2.56B
Net income	-3.73B -2.75M -2.43M -2.3M -2.08M -3.9M -264M -3.94M -27.55M -10.62M -135M -10.33M -10.1M -434M	-3.93B -2.9M -2.56M -2.42M -2.2M -4.12M -278M -4.16M -29.06M -11.2M -142M -10.89M -10.66M -457M
Net Debt	3.15B 2.32M 2.05M 1.94M 1.76M 3.29M 223M 3.32M 23.23M 8.95M 114M 8.71M 8.52M 366M	22.53B 16.61M 14.66M 13.87M 12.58M 23.59M 1.59B 23.82M 166M 64.14M 814M 62.38M 61.03M 2.62B